A Study to Investigate the Efficacy and Safety of Lusutrombopag (S-888711) Tablets Administered to Adults With Immune Thrombocytopenia (ITP)
Stopped This study was terminated before the planned sample size was enrolled because results indicated that a higher dose was necessary to elicit an efficacy effect.
Conditions
- Immune Thrombocytopenia (ITP)
Interventions
- DRUG: Placebo
- DRUG: Lusutrombopag
Sponsor
Shionogi